カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の組換えタンパク質医薬品CDMO市場（2023-2030）：種類別（成長ホルモン、インターフェロン、ワクチン、免疫賦活剤）、発生源別、疾患別、地域別

【英語タイトル】Recombinant Protein Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents), By Source, By Indication, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV236）・商品コード：GRV23NOV236
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：175
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

組換えタンパク質医薬品CDMO市場の成長と動向
Grand View Research, Inc.の最新レポートによると、組換えタンパク質医薬品CDMOの世界市場規模は2030年までに519億5000万米ドルに達する見込みで、2023年から2030年までのCAGRは13.9%で成長すると予測されています。慢性疾患の有病率の増加、バイオテクノロジーの進歩、個別化医療の台頭、生物医学研究開発投資の増加が市場成長の主な要因です。

組換えタンパク質医薬品に対する需要の高まりは、バイオ医薬品製造インフラや施設への投資を増加させています。これには、大規模生産施設の設立、プロセスの最適化、製造技術の改善などが含まれます。製造能力の拡大により、組換えタンパク質医薬品の生産量が増加し、市場の成長が促進されます。

組換えタンパク質医薬品の自社開発は、バイオ医薬品企業にとって時間とリソースを要するものです。CDMOにアウトソーシングすることで、企業は最先端の設備、専門的な知識、最適化されたプロセスを利用できるようになり、時間とコストの効率化が図れます。受託開発企業は能力を拡大し、迅速な納期を提供できるため、バイオ医薬品企業は製品をより迅速に市場に投入することができます。

COVID-19のパンデミックは市場に大きな影響を与えました。COVID-19治療薬とワクチンの需要は、組み換えタンパク質医薬品の製造能力を拡大しました。組換え蛋白質治療薬の開発に注力しているいくつかの企業は、COVID-19関連製品の要件を満たすために、プロセスや施設の規模を拡大しました。この拡大は、COVID-19治療薬やワクチンの生産を増強するだけでなく、組換えタンパク質医薬品CDMO業界における投資と成長の機会を創出しました。例えば、2021年2月、GSKとサノフィは、アジュバント組換えタンパク質COVID-19ワクチン候補の評価のための第2相試験の開始を発表しました。

組換えタンパク質医薬品CDMO市場レポートハイライト

- 2022年の最大シェアはインターフェロン分野で21.6%でした。慢性疾患や感染症の治療における組換えタンパク質インターフェロンの需要の高まりがセグメントを牽引しています。

- 供給源に基づくと、哺乳類系セグメントは2022年に67.3%の最大シェアを占めました。同分野のシェアが高い主な理由は、哺乳類由来の治療薬で外部委託の割合が増加しているためです。

- 腫瘍学セグメントは、予測期間中に14.8%という最も速いCAGRを記録すると予測されています。これは、がん治療における新規抗体の発見を目的とした臨床試験の割合が増加しているためです。

- アジア太平洋地域は、予測期間中に14.3%のCAGRを記録すると予測されています。インドや中国などのアジア諸国は、欧米諸国に比べて生産コストが比較的低いため、同地域全体でより多くの顧客層を惹きつけ、同地域の成長を支えています。

第1章. 調査方法・範囲
第2章. エグゼクティブサマリー
第3章. 市場変動・動向・範囲
第4章. 世界の組換えタンパク質医薬品CDMO市場：タイプ別予測・動向分析
第5章. 世界の組換えタンパク質医薬品CDMO市場：供給源別予測・動向分析
第6章. 世界の組換えタンパク質医薬品CDMO市場：疾患別予測・動向分析
第7章. 世界の組換えタンパク質医薬品CDMO市場：地域別予測・動向分析
第8章. 競争状況

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Content

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.1.2. Type
1.1.3. Source
1.1.4. Indication
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective – 1
1.4.2. Objective – 2
1.4.3. Objective – 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Recombinant Protein Therapeutics CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Rate of Clinical Research to Boost Demand for Recombinant Protein Therapeutics
3.2.1.2. Rising Adoption of Biologics and Biosimilars
3.2.1.3. Technological Innovations Pertaining to the Development of Novel Recombinant Protein Therapeutics
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory Hurdles
3.2.2.2. Challenges Related to Quality Control
3.3. Recombinant Protein Therapeutics CDMO Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat Of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Recombinant Protein Therapeutics CDMO Market: Type Estimates & Trend Analysis
4.1. Recombinant Protein Therapeutics CDMO Market, By Type: Segment Dashboard
4.2. Recombinant Protein Therapeutics CDMO Market, By Type: Movement Analysis
4.3. Recombinant Protein Therapeutics CDMO Market Estimates & Forecasts, By Type, 2018 – 2030
4.3.1. Growth Hormones
4.3.1.1. Growth Hormones Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
4.3.2. Interferons
4.3.2.1. Interferons Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
4.3.3. Vaccines
4.3.3.1. Vaccines Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
4.3.4. Immunostimulating Agents
4.3.4.1. Immunostimulating Agents Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
4.3.5. Others
4.3.5.1. Others Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
Chapter 5. Recombinant Protein Therapeutics CDMO Market: Source Estimates & Trend Analysis
5.1. Recombinant Protein Therapeutics CDMO Market, By Source: Segment Dashboard
5.2. Recombinant Protein Therapeutics CDMO Market, By Source: Movement Analysis
5.3. Recombinant Protein Therapeutics CDMO Market Estimates & Forecasts, By Source, 2018 – 2030
5.3.1. Mammalian Systems
5.3.1.1. Mammalian Systems Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
5.3.2. Microbial Systems
5.3.2.1. Microbial Systems Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
5.3.3. Others
5.3.3.1. Others Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
Chapter 6. Recombinant Protein Therapeutics CDMO Market: Indication Estimates & Trend Analysis
6.1. Recombinant Protein Therapeutics CDMO Market, By Indication: Segment Dashboard
6.2. Recombinant Protein Therapeutics CDMO Market, By Indication: Movement Analysis
6.3. Recombinant Protein Therapeutics CDMO Market Estimates & Forecasts, By Indication, 2018 – 2030
6.3.1. Oncology
6.3.1.1. Oncology Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.2. Infectious Diseases
6.3.2.1. Infectious Diseases Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.3. Immunological Disorders
6.3.3.1. Immunological Disorders Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.4. Metabolic Disorders
6.3.4.1. Metabolic Disorders Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.5. Haematological Disorders
6.3.5.1. Haematological Disorders Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.6. Others
6.3.6.1. Others Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
Chapter 7. Recombinant Protein Therapeutics CDMO Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2022 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. North America
7.4.1. Market Estimates and Forecast, 2018 – 2030 (Revenue, USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. U.S. Market Estimates and Forecasts, 2018 – 2030
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Canada Market Estimates and Forecasts, 2018 – 2030
7.5. Europe
7.5.1. UK
7.5.1.1. Key Country Dynamics
7.5.1.2. Competitive Scenario
7.5.1.3. Regulatory Framework
7.5.1.4. UK Market Estimates and Forecasts, 2018 – 2030
7.5.2. Germany
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Germany Market Estimates and Forecasts, 2018 – 2030
7.5.3. France
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. France Market Estimates and Forecasts, 2018 – 2030
7.5.4. Italy
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Italy Market Estimates and Forecasts, 2018 – 2030
7.5.5. Spain
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Spain Market Estimates and Forecasts, 2018 – 2030
7.5.6. Denmark
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Denmark Market Estimates and Forecasts, 2018 – 2030
7.5.7. Sweden
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Sweden Market Estimates and Forecasts, 2018 – 2030
7.5.8. Norway
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Framework
7.5.8.4. Norway Market Estimates and Forecasts, 2018 – 2030
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key Country Dynamics
7.6.1.2. Competitive Scenario
7.6.1.3. Regulatory Framework
7.6.1.4. Japan Market Estimates and Forecasts, 2018 – 2030
7.6.2. India
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. India Market Estimates and Forecasts, 2018 – 2030
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. China Market Estimates and Forecasts, 2018 – 2030
7.6.4. South Korea
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. South Korea Market Estimates and Forecasts, 2018 – 2030
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Australia Market Estimates and Forecasts, 2018 – 2030
7.6.6. Thailand
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. Thailand Market Estimates and Forecasts, 2018 – 2030
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key Country Dynamics
7.7.1.2. Competitive Scenario
7.7.1.3. Regulatory Framework
7.7.1.4. Brazil Market Estimates and Forecasts, 2018 – 2030
7.7.2. Mexico
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. Mexico Market Estimates and Forecasts, 2018 – 2030
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Argentina Market Estimates and Forecasts, 2018 – 2030
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key Country Dynamics
7.8.1.2. Competitive Scenario
7.8.1.3. Regulatory Framework
7.8.1.4. South Africa Market Estimates and Forecasts, 2018 – 2030
7.8.2. Saudi Arabia
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 – 2030
7.8.3. UAE
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. UAE Market Estimates and Forecasts, 2018 – 2030
7.8.4. Kuwait
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 – 2030
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.1.1. Innovators
8.1.2. Market Leaders
8.1.3. Emerging Players
8.1.4. Company Market Share Analysis, 2022
8.2. Company Profiles
8.2.1. Richter-Helm BioLogics
8.2.1.1. Company Overview
8.2.1.2. Financial Performance
8.2.1.3. Service Benchmarking
8.2.1.4. Strategic Initiatives
8.2.2. Lonza
8.2.2.1. Company Overview
8.2.2.2. Financial Performance
8.2.2.3. Service Benchmarking
8.2.2.4. Strategic Initiatives
8.2.3. Catalent, Inc
8.2.3.1. Company Overview
8.2.3.2. Financial Performance
8.2.3.3. Service Benchmarking
8.2.3.4. Strategic Initiatives
8.2.4. FUJIFILM Diosynth Biotechnologies
8.2.4.1. Company Overview
8.2.4.2. Financial Performance
8.2.4.3. Service Benchmarking
8.2.4.4. Strategic Initiatives
8.2.5. WuXi Biologics
8.2.5.1. Company Overview
8.2.5.2. Financial Performance
8.2.5.3. Service Benchmarking
8.2.5.4. Strategic Initiatives
8.2.6. Curia Global, Inc.
8.2.6.1. Company Overview
8.2.6.2. Financial Performance
8.2.6.3. Service Benchmarking
8.2.6.4. Strategic Initiatives
8.2.7. Batavia Biosciences B.V.
8.2.7.1. Company Overview
8.2.7.2. Financial Performance
8.2.7.3. Service Benchmarking
8.2.7.4. Strategic Initiatives
8.2.8. HALIX B.V.
8.2.8.1. Company Overview
8.2.8.2. Financial Performance
8.2.8.3. Service Benchmarking
8.2.8.4. Strategic Initiatives
8.2.9. AGC Biologics
8.2.9.1. Company Overview
8.2.9.2. Financial Performance
8.2.9.3. Service Benchmarking
8.2.9.4. Strategic Initiatives
8.2.10. Enzene Biosciences
8.2.10.1. Company Overview
8.2.10.2. Financial Performance
8.2.10.3. Service Benchmarking
8.2.10.4. Strategic Initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 North America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 4 North America Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 5 North America Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 6 North America Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 7 U.S. Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 8 U.S. Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 9 U.S. Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 10 Canada Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 11 Canada Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 12 Canada Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 13 Europe Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 14 Europe Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 15 Europe Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 16 Europe Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 17 U.K. Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 18 U.K. Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 19 U.K. Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 20 Germany Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 21 Germany Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 22 Germany Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 23 France Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 24 France Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 25 France Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 26 Italy Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 27 Italy Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 28 Italy Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 29 Spain Recombinant Protein Therapeutics CDMO market, by Source type, 2018 - 2030 (USD Million)
Table 30 Spain Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 31 Spain Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 32 Denmark Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 33 Denmark Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 34 Denmark Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 35 Sweden Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 36 Sweden Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 37 Sweden Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 38 Norway Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 39 Norway Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 40 Norway Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 45 China Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 46 China Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 47 China Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 48 Japan Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 49 Japan Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 50 Japan Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 51 India Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 52 India Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 53 India Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 54 Australia Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 55 Australia Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 56 Australia Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 57 South Korea Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 58 South Korea Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 59 South Korea Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 60 Thailand Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 61 Thailand Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 62 Thailand Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 63 Latin America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 64 Latin America Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 65 Latin America Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 66 Latin America Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 67 Brazil Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 68 Brazil Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 69 Brazil Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 70 Mexico Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 71 Mexico Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 72 Mexico Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 73 Argentina Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 74 Argentina Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 75 Argentina Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 76 Middle East and Africa Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 77 Middle East and Africa Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 78 Middle East and Africa Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 79 Middle East and Africa Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 80 South Africa Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 81 South Africa Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 82 South Africa Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 86 UAE Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 87 UAE Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 88 UAE Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 89 Kuwait Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 90 Kuwait Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 91 Kuwait Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market research approaches
Fig. 4 QFD modelling for market share assessment
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Primary research pattern
Fig. 8 Primary interviews in North America
Fig. 9 Primary interviews in Europe
Fig. 10 Primary interviews in Asia Pacific
Fig. 11 Primary interviews in Latin America
Fig. 12 Primary interviews in MEA
Fig. 13 Market Snapshot
Fig. 14 Segment Snapshot
Fig. 15 Segment Snapshot
Fig. 16 Competitive Landscape Snapshot
Fig. 17 Recombinant Protein Therapeutics CDMO market segmentation
Fig. 18 Parent market outlook (2022)
Fig. 19 Related/ancillary market outlook (2022)
Fig. 20 Market driver relevance analysis (Current & future impact)
Fig. 21 Market restraint relevance analysis (Current & future impact)
Fig. 22 Porter’s five forces analysis
Fig. 23 SWOT analysis, by a factor (political & legal, economic and technological)
Fig. 24 Recombinant Protein Therapeutics CDMO Market Type outlook: Segment dashboard
Fig. 25 Recombinant Protein Therapeutics CDMO :Type movement analysis
Fig. 26 Growth Hormones market, 2018 - 2030 (USD Million)
Fig. 27 Interferons market, 2018 - 2030 (USD Million)
Fig. 28 Vaccines market, 2018 - 2030 (USD Million)
Fig. 29 Immunostimulating Agents market, 2018 - 2030 (USD Million)
Fig. 30 Others market, 2018 - 2030 (USD Million)
Fig. 31 Recombinant Protein Therapeutics CDMO Market Source outlook: Segment dashboard
Fig. 32 Recombinant Protein Therapeutics CDMO : Source type movement analysis
Fig. 33 Mammalian Systems market, 2018 - 2030 (USD Million)
Fig. 34 Microbial Systems market, 2018 - 2030 (USD Million)
Fig. 35 Others market, 2018 - 2030 (USD Million)
Fig. 36 Recombinant Protein Therapeutics CDMO market Indication outlook: Segment dashboard
Fig. 37 Recombinant Protein Therapeutics CDMO market: Indication movement analysis
Fig. 38 Oncology market, 2018 - 2030 (USD Million)
Fig. 39 Infectious Diseases market, 2018 - 2030 (USD Million)
Fig. 40 Immunological Disorders market, 2018 - 2030 (USD Million)
Fig. 41 Metabolic Disorders market, 2018 - 2030 (USD Million)
Fig. 42 Haematological Disorders market, 2018 - 2030 (USD Million)
Fig. 43 Others market, 2018 - 2030 (USD Million)
Fig. 44 Regional marketplace: Segment dashboard
Fig. 45 Regional outlook, 2022 & 2030
Fig. 46 North America market, 2018 - 2030 (USD Million)
Fig. 47 U.S. market, 2018 - 2030 (USD Million)
Fig. 48 Canada market, 2018 - 2030 (USD Million)
Fig. 49 Europe market, 2018 - 2030 (USD Million)
Fig. 50 Germany market, 2018 - 2030 (USD Million)
Fig. 51 UK market, 2018 - 2030 (USD Million)
Fig. 52 France market, 2018 - 2030 (USD Million)
Fig. 53 Italy market, 2018 - 2030 (USD Million)
Fig. 54 Spain market, 2018 - 2030 (USD Million)
Fig. 55 Denmark market, 2018 - 2030 (USD Million)
Fig. 56 Sweden market, 2018 - 2030 (USD Million)
Fig. 57 Norway market, 2018 - 2030 (USD Million)
Fig. 58 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 59 China market, 2018 - 2030 (USD Million)
Fig. 60 Japan market, 2018 - 2030 (USD Million)
Fig. 61 India market, 2018 - 2030 (USD Million)
Fig. 62 Australia market, 2018 - 2030 (USD Million)
Fig. 63 Thailand market, 2018 - 2030 (USD Million)
Fig. 64 South Korea market, 2018 - 2030 (USD Million)
Fig. 65 Latin America market, 2018 - 2030 (USD Million)
Fig. 66 Brazil market, 2018 - 2030 (USD Million)
Fig. 67 Mexico market, 2018 - 2030 (USD Million)
Fig. 68 Argentina market, 2018 - 2030 (USD Million)
Fig. 69 Middle East & Africa market, 2018 - 2030 (USD Million)
Fig. 70 South Africa market, 2018 - 2030 (USD Million)
Fig. 71 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 72 UAE market, 2018 - 2030 (USD Million)
Fig. 73 Kuwait market, 2018 - 2030 (USD Million)

★調査レポート[世界の組換えタンパク質医薬品CDMO市場（2023-2030）：種類別（成長ホルモン、インターフェロン、ワクチン、免疫賦活剤）、発生源別、疾患別、地域別] (コード：GRV23NOV236)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の組換えタンパク質医薬品CDMO市場（2023-2030）：種類別（成長ホルモン、インターフェロン、ワクチン、免疫賦活剤）、発生源別、疾患別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のバイオ医薬品市場（～2030年）：製品種類別（モノクローナル抗体、インターフェロン、インスリン、成長・凝固因子、ワクチン、組み換え成長因子、精製タンパク質、組み換えタンパク質、合成免疫調節剤、組み換えホルモン、組み換え酵素、細胞・遺伝子治療、合成免疫調節剤、その他）、用途別、地域別
  • 世界のタンパク質工学市場2023-2030：製品別（試薬、機器）、タンパク質タイプ別（インスリン、ワクチン）、エンドユーザー別（CRO、製薬＆バイオテクノロジー企業）、技術別
  • 世界の生物学的安全性試験製品・サービス市場2023-2030：製品別（試薬・キット、サービス）、用途別（ワクチン・治療薬、遺伝子治療）、試験タイプ別、地域別
  • 世界の食品廃棄物管理市場2023-2030：廃棄物別（果物、野菜）、発生源別、サービスタイプ別、地域別
  • 世界の核酸治療薬CDMO市場（2023-2030）：種類別、サービス別（プロセス開発・最適化、製造サービス）、エンドユーザー別、用途別、地域別
  • 世界のペプチド薬物複合体（PDC）市場（2023-2030）：製品別（ルテチウム、メルフルフェン、ANG1005、BT1718、CBX-12、その他）、種類別（診断薬、治療薬）、地域別
  • 生物製剤のグローバル市場（2023～2028）：モノクローナル抗体、ワクチン、組み換えホルモン/タンパク質、細胞性生物製剤、その他

    • ◆H&Iグローバルリサーチのお客様（例）◆